APA (7th ed.) Citation

Sivakumaran, T., Mileshkin, L., Grant, P., Na, L., DeFazio, A., Friedlander, M., . . . Au-Yeung, G. (2020). Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study. Gynecologic Oncology, 158(1), 47. https://doi.org/10.1016/j.ygyno.2020.04.706

Chicago Style (17th ed.) Citation

Sivakumaran, T., L. Mileshkin, P. Grant, L. Na, A. DeFazio, M. Friedlander, A. Obermair, P.M Webb, and G. Au-Yeung. "Evaluating the Impact of Dose Reductions and Delays on Progression-free Survival in Women with Ovarian Cancer Treated with Either Three-weekly or Dose-dense Carboplatin and Paclitaxel Regimens in the National Prospective OPAL Cohort Study." Gynecologic Oncology 158, no. 1 (2020): 47. https://doi.org/10.1016/j.ygyno.2020.04.706.

MLA (9th ed.) Citation

Sivakumaran, T., et al. "Evaluating the Impact of Dose Reductions and Delays on Progression-free Survival in Women with Ovarian Cancer Treated with Either Three-weekly or Dose-dense Carboplatin and Paclitaxel Regimens in the National Prospective OPAL Cohort Study." Gynecologic Oncology, vol. 158, no. 1, 2020, p. 47, https://doi.org/10.1016/j.ygyno.2020.04.706.